Brain and CNS Cancer. Measurability of Quality Performance Indicators Version 3.0
|
|
- Oliver Jonas Lewis
- 5 years ago
- Views:
Transcription
1 Brain and CNS Cancer Measurability of Quality Permance Indicators Version 3.0 To be read in conjunction with: Brain and Central Nervous System Cancer Clinical Quality Permance Indicators Brain and Central Nervous System Cancer Data Definitions (latest published version) Brain/CNS Cancer QPI Measurability v3.0 1
2 Measurability of Quality Permance Indicators Brain & CNS Cancer Please refer to the Brain and CNS Cancer Quality Permance Indicators published by Healthcare Improvement Scotland a full description of individual QPIs Please refer to the Brain and CNS Cancer QPI Dataset published by ISD Scotland a full description of individual data items Document control: This version Title Brain & CNS Cancer Measurability of QPIs Version/Issue Number 3.0 Effective From January 2017 Author Jane Garrett, ISD Document Type Guidance Document status Final Document Purpose Publication Summary of changes Final V3.0 DATE Final In addition to reporting by Hospital of Diagnosis, the following QPIs should also be reported by Board of Surgery: 3 (a/b), 6, 7, 13 (surgery only) Revision History Version Date Status Summary of Changes QPI (s) 0.1 June 2013 Draft First version All 0.2 Dec 2013 Draft Changes following public engagement 1.2 June 2014 Final Amendments made out-with review, incorporating additional data item into the dataset updating the MDT 2 QPI. 2.0 Nov 2014 Final Change to version number due to changes in dataset n/a 2.1 May 2015 Final Amendments made out-with review 1, 2, August 2015 Final Amendments made out-with review 6,9 2.3 March 2016 Final Amendments made following Baseline Review 3,5,6,7,8,9, April 2018 Final Amendments following Formal Review. NB: Formal Review measurability changes apply to patients diagnosed in year 4 data collection (01/01/ /12/2017) with the exception of measures which require new data items. These changes will apply to patients diagnosed in year 5 data collection (01/01/ /12/2018). This will apply to the QPI s listed: Brain/CNS Cancer QPI Measurability v3.0 2 Year 4: 1, 8, 13 Year 5: 2, 3, 4, 5, 6, 7, 9, 10, 11, 12 Updates from Previous Version QPI Summary of changes (excluding matting changes) (April 2018) 2 QPI Title: change definitive management to any surgical procedure* ; Desc: change definitive management to surgery ; Num: change definitive management to surgery ; change Date of Definitive Treatment OR Date of Definitive Treatment is equal to not applicable. to Date of First Surgical Procedure ; change DEFTREATDATE] OR [DEFTREATDATE = 10/10/1010]) to DFIRSTSURG ; Den: add undergoing surgery, AND Date of First Surgical Procedure not coded as inapplicable, [DFIRSTSURG <> 10/10/1010] AND; NRnum delete [DEFTREATDATE = 09/09/0909] ; NRden add OR [DFIRSTSURG = 09/09/0909] ; Add Note *Please note that surgical procedures include diagnostic biopsies.
3 3 Desc: change analysis to analysis a ; Num(i) add Grade II or III ; change with an oligodendroglial 1 component to undergoing surgery ; Den(i) add Grade II or III ; delete with an oligodendrogliala component ; delete Mixed, NOS; Oligodendroglioma, anaplastic ; delete or Grade IV ; add 9400/3 OR 9411/3 OR 9401/3 OR 9440/3 OR 9441/3 OR 9442/3 OR 9445/3 OR 9385/3 OR 9425/3 OR 9431/3 OR 9430/3 OR ; delete 9382/3 OR and OR 4 ; Num(ii) add undergoing surgery ; Note: delete This includes -oligodendroglioma (WHO Grade II) - anaplastic oligodendroglioma (WHO Grade III) - oligoastrocytomas (WHO Grade II)- anaplastic oligoastrocytoma (WHO Grade III) - glioblastoma with an oligodendroglial component (WHO Grade IV) ; add WHO classification of CNS tumours (2016) uses molecular parameters in addition to histology to define tumour entities. In addition to those outlined in the QPI, relevant molecular analysis also include those outlined in 2016 World Health Organisation Classification of Tumours of the Central Nervous System. 4 QPI Title: add tumour type as described in World Health Organisation (WHO) Classification of CNS tumours (2016) and WHO grade where appropriate) ; Desc: delete diagnosed ; add brackets to as defined by the Royal College of Pathologists ; Num: add brackets to as defined by the Royal College of Pathologists 5 QPI Title: add contrast enhanced ; Desc: change resection and/or radical radiotherapy or chemotherapy to surgery ; add contrast enhanced ; Num: change resection of tumour, radical radiotherapy or chemotherapy to surgery ; add contrast enhanced ; add AND Date MRI Scan (Pre-treatment) is bee or equal to Date of First Surgical Procedure and add AND [MRIDATE DFIRSTSURG] ; Den: change resection of tumour, radical radiotherapy or chemotherapy to surgery ; add contrast enhanced ; delete Cerebral aneurysm clip; Metal in eye; and delete Unable to fit bore of scanner; Too heavy MRI table) ; add Date of First Surgical Procedure not coded as inapplicable ; delete (Main Type of Definitive Surgery{Brain/CNS Cancer} 1-4 coded as Craniotomy lesion of frontal lobe, Craniotomy lesion of temporal lobe, Craniotomy lesion of parietal lobe, Craniotomy lesion of occipital lobe, Craniotomy lesion of cerebellum, Craniotomy lesion of brain tissue - other site, or Craniotomy lesion of cerebellum; OR Radiotherapy Course Type {Brain/CNS Cancer} 1-2 coded as Radical, or Chemoradiotherapy; OR Type of Systemic Anti- Cancer Therapy (SACT) (Brain/CNS Cancer) 1-2 coded as Neoadjuvant, or Chemoradiotherapy; ; add [DFIRSTSURG <> 10/10/1010] ; delete ( [OPCODE1 OR OPCODE2 OR OPCODE3 OR OPCODE4 = A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.8 OR A02.5] OR [RADIO1 OR RADIO2 = 3 OR 7] OR [CHEMTYPE1 OR CHEMTYPE2 = 02 OR 05] ); NRNum: add OR [MRIDATE] ; NR Den: add [DFIRSTSURG = 09/09/0909] delete [OPCODE1 OR OPCODE2 OR OPCODE3 OR OPCODE4 = 99] OR [RADIO1 OR RADIO2 = 99] OR [CHEMTYPE1 OR CHEMTYPE2 = 99] 6 Desc: change maximal surgical resection (>90% resection of the measurable enhancing component) to surgical resection where 90% reduction in tumour volume is achieved ; Num: change >90% to 90% ; delete 99% or ; change 3 OR 4 to 5 ; Den: add and Patients in whom surgeons intent is partial resection / debulking surgery) ; delete NOS ; add Anaplastic astrocytoma, Gliosarcoma, Oligoastrocytoma, Anaplastic, Oligoastrocytoma, Anaplastic pleomorphic xanthoastrocytoma, Anaplastic ependymoma ; change AND Post Surgical MRI coded as Yes to AND Intent of Surgery not coded as partial resection / debulking surgery ; delete 9382/3 ; add 9401/3 OR 9445/3 OR 9424/3 OR 9392/3 ; change [POSTMRI = 1] to [OPINTENT <> 2] ; Note: delete Mixed tumours e.g. oligoastrocytoma, glioblastoma with oligodenroglial component ; add Anaplastic pleomorphic xanthoastrocytoma ; add Anaplastic ; Spec(ii): delete Num(ii); delete Den(ii); NRExcl: change N/A to [OPINTENT = 99] ; NRDen(i): delete [POSTMRI = 99] ; delete NRDen(ii) 7 Num: change receiving MRI to who receive MRI ; Den: delete Metal in eye; Claustrophobia;Unable to fit bore of scanner; Too heavy MRI table); delete NOS ; add Anaplastic astrocytoma, Gliosarcoma, Oligoastrocytoma; Anaplastic Oligoastrocytoma; Anaplastic pleomorphic xanthoastrocytoma; Anaplastic ependymoma ; delete 9382/3 ; add 9401/3 OR 9445/3 OR 9424/3 OR 9392/3 ; Note: delete Mixed tumours e.g. oligoastrocytoma, glioblastoma with oligodenroglial component ; add Anaplastic pleomorphic xanthoastrocytoma ; add Anaplastic 9 Den: delete NOS ; add Anaplastic astrocytoma, Gliosarcoma, Oligoastrocytoma; Anaplastic Oligoastrocytoma; Anaplastic pleomorphic xanthoastrocytoma; Anaplastic ependymoma ; delete 9382/3 ; add 9401/3 OR 9445/3 OR 9424/3 OR 9392/3 ; 10 QPI Title: change primary brain/cns cancer to brain/central Nervous System (CNS) cancer ; Desc: change primary brain/central nervous system (CNS) to brain/cns ; Den: delete primary and Metal in eye; Claustrophobia; Unable to fit bore of scanner; Too heavy MRI table ; Note: add 1 Radical is defined as radiotherapy courses where 15 fractions are delivered. 11 QPI Title: change a nurse with expertise in epilepsy management to named epilepsy specialist nurse (ESN) ; Desc: change nurse with expertise in epilepsy management to named ESN within four weeks of diagnosis ; Num: change nurse with expertise in epilepsy management to named ESN within four weeks of diagnosis ; change Nurse with expertise in epilepsy management to Named Epilepsy Specialist Nurse (ESN) ; change nurse with expertise in epilepsy management to Named Epilepsy Specialist Nurse ; add AND Date seen by Neurologist and/or Named Epilepsy Specialist Nurse minus Date of Diagnosis less than or equal to 28 days ; add AND [EPILNESNDATE DIAGDATE 28] ; NRNum: add OR [EPILNESNDATE = 09/09/0909] 12 Inserted New QPI - Key Worker 13 Inserted New QPI - 30 Day Mortality after Treatment Brain/CNS Cancer QPI Summary of changes (excluding matting changes) (March 2016) Brain/CNS Cancer QPI Measurability v3.0 3
4 3 Description, Numerator & Denominator changed reference numbers to letters and inserted reference text to align with the QPI document - a This includes: - oligodendroglioma (WHO Grade II) - anaplastic oligodendroglioma (WHO Grade III) - oligoastrocytomas (WHO Grade II) - anaplastic oligoastrocytoma (WHO Grade III) - glioblastoma with an oligodendroglial component (WHO Grade IV) b including subtypes (WHO Grade IV) c The O(6)-methylguanine-DNA methyltransferase (MGMT) gene 5 Denominator removed and Patients undergoing biopsy only ; Main type of Definitive Operation changed to Main Type of Definitive Surgery ; deleted SCAN from MRI SCAN changed equation from [SCAN <> (95 OR...)] to [MRI <> (95 OR...)] 6 Deleted high grade (world health organisation (WHO) Grades III and IV) from QPI title and inserted d after malignant gliomas. Description deleted high grade and after malignant glioma inserted d (with enhancing component on pre-operative imaging) also after 90% inserted resection of the measurable enhancing component Numerator and Denominator have now been split into 2 specifications. Numerator (i) is Number of patients with resectable malignant gliomad (with enhancing component on pre-operative imaging) undergoing surgical resection where >90%* reduction in tumour volume is achieved. Denominator (i) is All patients with malignant gliomad (with enhancing component on pre-operative imaging) undergoing surgical resection. (Excluding patients undergoing biopsy only 1 ). Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Morphology of Tumour coded as Glioblastoma, NOS; Giant cell glioblastoma, Oligodendroglioma, NOS; Oligodendroglioma, anaplastic; AND Main Type of Definitive Surgery {Brain/CNS Cancer} coded as Craniotomy lesion of frontal lobe, Craniotomy lesion of temporal lobe, Craniotomy lesion of parietal lobe, Craniotomy lesion of occipital lobe, Craniotomy lesion of cerebellum, Craniotomy lesion of brain tissue - other site AND Enhancing component present on pre-operative imaging coded as yes AND Post Surgical MRI coded as Yes - [MORPHOL = 9440/3 OR 9441/3 OR 9442/3 OR 9382/3 OR 9450/3 OR 9451/3] AND [OPCODE1 OR OPCODE2 OR OPCODE3 OR OPCODE4 = A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8] AND [ENHANC = 1] AND [POSTMRI = 1]. Numerator (ii) is Number of patients with resectable malignant glioma d (with enhancing component on pre-operative imaging) undergoing surgery (biopsy and surgical resection) where >90%* reduction in tumour volume is achieved. - Reduction in Tumour Volume {Brain/CNS Cancer} coded as 90-99% or 100% - [REDUCT = 3 OR 4]. Denominator (ii) is All patients with malignant glioma d (with enhancing component on pre-operative imaging) undergoing surgery (biopsy and surgical resection) (No exclusions).- Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Morphology of Tumour coded as Glioblastoma, NOS; Giant cell glioblastoma, Oligodendroglioma, NOS; Oligodendroglioma, anaplastic; AND Main Type of Definitive Surgery {Brain/CNS Cancer} coded as Craniotomy lesion of frontal lobe, Craniotomy lesion of temporal lobe, Craniotomy lesion of parietal lobe, Craniotomy lesion of occipital lobe, Craniotomy lesion of cerebellum, Craniotomy lesion of brain tissue - other site, Biopsy only AND Enhancing component present on pre-operative imaging coded as yes AND Post Surgical MRI coded as Yes - [MORPHOL = 9440/3 OR 9441/3 OR 9442/3 OR 9382/3 OR 9450/3 OR 9451/3] AND [OPCODE1 OR OPCODE2 OR OPCODE3 OR OPCODE4 = A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98] AND [ENHANC = 1] AND [POSTMRI = 1]. NR Exclusion replaced [OPCODE1 OR OPCODE2 OR OPCODE3 OR OPCODE4 =99] with N/A; NR Denominator changed to 2 specs (i) [MORPHOL = 9999/9] OR [OPCODE1 = 99 AND OPCODE2-4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8) OR OPCODE2 = 99 AND OPCODE1, 3, 4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8) OR OPCODE3 = 99 AND OPCODE 1, 2, 4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8) OR OPCODE4 = 99 AND OPCODE1-3 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8)] OR [ENHANC = 99] OR [POSTMRI = 99] and (ii) [MORPHOL = 9999/9] OR [OPCODE1 = 99 AND OPCODE2-4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98) OR OPCODE2 = 99 AND OPCODE1, 3, 4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98) OR OPCODE3 = 99 AND OPCODE 1, 2, 4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98) OR OPCODE4 = 99 AND OPCODE1-3 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98)] OR [ENHANC = 99] OR [POSTMRI = 99] References have now changed from Malignant gliomas include: Grade IV (Glioblastoma multime- GBM and its variants e.g. gliosarcoma), Grade III (Anaplastic Astrocytoma- AA), Grade III anaplastic oligodendrogliomas, Grade III or IV mixed tumours e.g. oligoastrocytoma, glioblastoma with oligodenroglial component, Highgrade ependymoma To d Malignant gliomas include: Glioblastoma multime- GBM and its variants e.g. gliosarcoma, Anaplastic Astrocytoma- AA, Anaplastic oligodendrogliomas, Mixed tumours e.g.oligoastrocytoma, glioblastoma with oligodenroglial component, High-grade ependymoma e Patients undergoing biopsy only are excluded by default due to the operation codes used within this measurability * Percentage tumour reduction should be assessed by comparing pre surgical imaging to post surgical 72hr Magnetic Resonance Imaging (MRI) 7 QPI title, Description and Numerator inserted d after malignant glioma, removed (WHO Grades II, III and IV) and inserted (with enhancing component on pre-operative imaging); Denominator inserted d after malignant glioma, removed (WHO Grades II, III and IV) and inserted (with enhancing component on pre-operative imaging), deleted AND WHO Grade coded as Grade II, Grade III or Grade IV, Main type of Definitive Operation changed to Main Type of Definitive Surgery, removed or Craniotomy lesion of cerebellum, inserted Enhancing component present on pre-operative imaging coded as yes; AND, removed Not applicable patients undergoing biopsy only, removed AND [GRADE = 2 OR 3 OR 4], OPCODE OR A02.5, POSTMRI OR 96 inserted AND [ENHANC =1]; NR Denominator removed OR [GRADE = 99] and inserted OR [ENHANC = 99] Reference d Malignant gliomas include: Glioblastoma multime- GBM and its variants e.g. gliosarcoma, Anaplastic Astrocytoma- AA, Anaplastic oligodendrogliomas, Mixed tumours e.g.oligoastrocytoma, glioblastoma with oligodenroglial component, High-grade ependymoma is now inserted. 8 Denominator removed radiotherapy course type coded as Adjuvant, Neo adjuvant 1 OR 2 OR 9 Changed from Access to Adjuvant Treatment to Access to Oncological Treatment ; QPI Title removed surgical resection and inserted surgery ; Description changed surgical resection to surgery throughout and receive to commence ; Numerator changed from Number of patients with high grade glioma (WHO grades III and IV) Brain/CNS Cancer QPI Measurability v3.0 4
5 who undergo surgical resection who commence oncological treatment (chemotherapy, radiotherapy or chemoradiotherapy) within 6 weeks of surgical resection. - Radiotherapy Course Type {Brain/CNS Cancer} 1; or Type of Systemic Anti-Cancer Therapy (SACT) {Brain/CNS Cancer} 1 coded as adjuvant or chemoradiotherapy; AND Date Treatment Started {Cancer} (Radiotherapy) 1; or Date Treatment Started Systemic Anti-Cancer Therapy (SACT) 1 minus Date of Definitive Surgery is less than or equal to 42 - ( [RADIO1 = 1 OR 7] AND [RADDATE1 DSURG 42] ) OR ( [CHEMTYPE1 = 1 OR 5] AND [CHEMDATE1 DSURG 42] ) To Number of patients with high grade glioma (WHO grades III and IV) who undergo oncological treatment (chemotherapy, radiotherapy or chemoradiotherapy) who commence treatment within 6 weeks of surgery. - Date Treatment Started {Cancer} (Radiotherapy) 1; or Date Treatment Started Systemic Anti-Cancer Therapy (SACT) 1 minus Date of Definitive Surgery is less than or equal to 42 - [RADDATE1 DSURG 42] OR [CHEMDATE1 DSURG 42] ) ; Denominator changed from All patients with high grade glioma (WHO grades 3 and 4) who undergo surgical resection. (No exclusions) - Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Morphology of Tumour coded as Glioblastoma, NOS; Giant cell glioblastoma, Oligodendroglioma, NOS; Oligodendroglioma, anaplastic; AND WHO Grade coded as Grade III or Grade IV; AND Main Type of Definitive Surgery {Brain/CNS Cancer} 1-4 coded as Craniotomy lesion of; frontal lobe, temporal lobe, parietal lobe, occipital lobe, cerebellum or brain tissue other site. - [MORPHOL = 9382/3 OR 9440/3 OR 9441/3 OR 9442/3 OR 9450/3 OR 9451/3] AND [GRADE = 3 OR 4] AND ([OPCODE1 OR OPCODE2 OR OPCODE3 OR OPCODE4 = A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8]) ; NR Numerator equation changed from [RADDATE1 = 09/09/0909] OR [CHEMDATE1 = 09/09/0909] OR [DSURG = 09/09/0909] OR [RADIO1 = 99] OR [CHEMTYPE1 = 99] To ([RADDATE1 = 09/09/0909] AND [CHEMDATE1 = 09/09/0909]) OR [DSURG = 09/09/0909] ; NR Denominator equation changed from [MORPHOL = 9999/9] OR [GRADE = 99] OR [OPCODE1 OR OPCODE2 OR OPCODE3 OR OPCODE4 = 99] To [MORPHOL = 9999/9] OR [GRADE = 99] OR [OPCODE1 = 99 AND OPCODE2-4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98) OR OPCODE2 = 99 AND OPCODE1, 3, 4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98) OR OPCODE3 = 99 AND OPCODE 1, 2, 4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98) OR OPCODE4 = 99 AND OPCODE1-3 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98)] OR [(RADIO1 = 99 AND CHEMTYPE1 <>(1 OR 5)] OR [(CHEMTYPE1 = 99 AND RADIO1 <> (3 OR 7)] 10 Denominator added Chemoradiotherapy Radiotherapy Course Type [RADIO1 OR RADIO2 = 3 OR 7] QPI Summary of changes (excluding matting changes) (August 2015) 6 Remove duplicate 'or Craniotomy lesion of cerebellum' and duplicate opcode 'OR A NR Denominator MORPHOL = 9999/9 instead of 99 and OPCODE = 99 instead of 9999/9. QPI Summary of changes (excluding matting changes) (May 2015) 1 NR Num changed to [PSTATUS <>9] AND ([WHODATE = 09/09/0909] OR [MDTDATE = 09/09/0909]), NR Den changed to [ICDSITE = C99.X] OR [MDTDATE = 09/09/0909] 2 Numerator changed to [MDTDATE <> 10/10/1010] AND ([MDTDATE DEFTREATDATE] OR [DEFTREATDATE = 10/10/1010]) 9 RADIO2 and CHEMTYPE2 removed, chemoradiotherapy added QPI Summary of changes (excluding matting changes) (June 2014) 2 Inserted new MDT QPI. 8 Numerator amended Specialist Neuro-oncologist {Brain/CNS Cancer} coded as Yes [SPECNEURO = 01], NR Numerator amended [SPECNEURO = 99] Brain/CNS Cancer QPI Measurability v3.0 5
6 QPI 1 - Documentation of Permance Status QPI Title: Numerator: Patients with newly-diagnosed brain/central nervous system (CNS) cancer should have a world health organisation (WHO) permance status documented at time of diagnosis. Proportion of newly-diagnosed patients with brain/cns cancer who have a documented WHO permance status at the time of multidisciplinary team (MDT) discussion. Number of newly-diagnosed patients with brain/cns cancer discussed at MDT meeting with a documented WHO permance status at the time of MDT discussion. WHO/ECOG Permance Status not coded as Not Applicable; AND Date of Assessment of WHO/ECOG Permance Status (KPS) is less than or equal to Date Discussed by Care Team (MDT) [PSTATUS <> 9] AND [WHODATE MDTDATE] Denominator: All newly-diagnosed patients with brain/cns cancer discussed at MDT meeting (No exclusions). Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Site of Origin of Primary Tumour {Brain/CNS Cancer} 1-4 coded as Brain/CNS Cancer; AND Date Discussed by Care Team (MDT) not coded as Inapplicable [ICDSITE = C700 OR C701 OR C709 OR C71 OR C72 OR C75.2 OR C75.3] AND [MDTDATE <> 10/10/1010] numerator exclusion Include in the denominator measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [PSTATUS <>9] AND ([ WHODATE = 09/09/0909] OR [MDTDATE = 09/09/0909]) Include in the denominator measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion this standard. N/A denominator Exclude from the denominator measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion this standard [ICDSITE = C99.X] Brain/CNS Cancer QPI Measurability v3.0 6
7 QPI 2 Multi-Disciplinary Team Meeting QPI Title: Numerator: Patients with brain/cns cancer should be discussed by a multidisciplinary (MDT) team prior to any surgical procedure*. Proportion of patients with brain/cns cancer who are discussed at MDT meeting bee surgery. Number of patients with brain/cns cancer discussed at the MDT bee surgery. Date Discussed by Care Team (MDT) not coded as not applicable; AND Date Discussed by Care Team (MDT) is bee or equal to Date of First Surgical Procedure [MDTDATE <> 10/10/1010] AND [MDTDATE DFIRSTSURG] Denominator: All patients with Brain/CNS cancer undergoing surgery (Excluding patients who died bee first treatment). Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Site of Origin of Primary Tumour {Brain/CNS Cancer} 1-4 coded as Brain/CNS Cancer; AND Date of First Surgical Procedure not coded as inapplicable ; AND Type of First Treatment not coded as Patient died bee treatment. [ICDSITE = C70.0 OR C70.1 OR C70.9 OR C71 OR C72 OR C75.2 OR C75.3] AND [DFIRSTSURG <> 10/10/1010] AND [FIRSTTREATTYPE <>94] numerator exclusion denominator Include in the denominator measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [MDTDATE = 09/09/0909] Include in the denominator measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion this standard. [FIRSTTREATTYPE = 99] Exclude from the denominator measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion this standard [ICDSITE = C99.X] OR [DFIRSTSURG = 09/09/0909] *Please note that surgical procedures include diagnostic biopsies. Brain/CNS Cancer QPI Measurability v3.0 7
8 b c QPI 3 Molecular Analysis QPI Title: Patients with biopsied or resected gliomas should have molecular analysis permed on the tumour tissue within 21 days of surgery to inm treatment decision making. Proportion of patients with biopsied or resected gliomas who undergo relevant molecular analysis a of tumour tissue within 21 days of surgery. Please note: This QPI measures 2 distinct elements: (i): Patients with Grade II or III gliomas who have the tumour tested combined loss of 1p/19q; and (ii): Patients with glioblastomas b who have the tumour tested MGMT c promoter methylation status. Specification (i) Numerator (i) Number of patients with a Grade II or III glioma undergoing surgery where tissue sample is tested 1p/19q within 21 days of surgery. 1P/19Q Tissue Analysis {Brain/CNS Cancer} not coded as Not Done or Insufficient Sample; and Date of 1P/19Q Tissue Analysis {Brain/CNS Cancer} minus Date of Definitive Surgery less than or equal to 21 days Denominator (i) [SAMP1P <> 03 OR 04] AND [SAMP1PDATE DSURG 21] All patients with a Grade II or III glioma undergoing surgery (No exclusions). Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Morphology of Tumour coded as Glioma; Oligodendroglioma; AND WHO Grade coded as Grade II or Grade III ; and Date of Definitive Surgery not coded as Inapplicable. [MORPHOL = 9400/3 OR 9411/3 OR 9401/3 OR 9440/3 OR 9441/3 OR 9442/3 OR 9445/3 OR 9385/3 OR 9425/3 OR 9431/3 OR 9430/3 OR 9450/3 OR 9451/3] AND [GRADE = 2 OR 3] AND [DSURG <> 10/10/1010] WHO classification of CNS tumours (2016) uses molecular parameters in addition to histology to define tumour entities. In addition to those outlined in the QPI, relevant molecular analysis also include those outlined in 2016 World Health Organisation Classification of Tumours of the Central Nervous System. - b including subtypes (WHO Grade IV) c The O(6)-methylguanine-DNA methyltransferase (MGMT) gene a Brain/CNS Cancer QPI Measurability v3.0 8
9 Specifications (ii): Numerator (ii) Number of patients with glioblastomas undergoing surgery where tissue sample is assessed MGMT promoter hypermethylation status within 21 days of surgery. MGMT Tissue Analysis not coded as Not Done or Insufficient Sample; and Date of MGMT Tissue Analysis minus Date of Definitive Surgery less than or equal to 21 days Denominator (ii) [MGMTSAMP <> 03 OR 04] AND [MGMTSAMPDATE DSURG 21] All patients with glioblastomas undergoing surgery (No exclusions). Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Morphology of Tumour coded as Glioblastoma, NOS; Giant cell glioblastoma; or Gliosarcoma (Glioblastoma with Sarcomatous Component); AND WHO Grade coded as Grade IV, and Date of Definitive Surgery not coded as Inapplicable. [MORPHOL = 9440/3 OR 9441/3 OR 9442/3] AND [GRADE = 4] AND [DSURG <> 10/10/1010] numerator Include in the denominator measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target (i) [SAMP1P = 99] OR [SAMP1PDATE = 09/09/0909] OR [DSURG = 09/09/0909] (ii) [MGMTSAMP = 99] OR [MGMTSAMPDATE = 09/09/0909] OR [DSURG = 09/09/0909] exclusion Include in the denominator measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion this standard. (i) and (ii) N/A denominator Exclude from the denominator measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion this standard (i) and (ii) [MORPHOL = 9999/9] OR [GRADE = 99] OR [DSURG = 09/09/0909] Brain/CNS Cancer QPI Measurability v3.0 9
10 QPI 4 Neuropathological Diagnosis QPI Title: Numerator: All pathology reports brain/central nervous system (CNS) cancer should contain full pathology inmation (including tumour type as described in World Health Organisation (WHO) Classification of CNS tumours (2016) and WHO grade where appropriate) to inm patient management. Proportion of patients with brain/cns cancer where the pathology report contains a full set of data items (as defined by the Royal College of Pathologists). Number of patients with a histological diagnosis of brain/cns cancer where histological pathology report contains all data items (as defined by relevant Royal College of Pathologists publication). Histopathology Report Complete {Brain/CNS Cancer} coded as Complete [PATHCOMPL = 1] Denominator: All patients with a histological diagnosis of brain/cns cancer (No exclusions). Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Site of Origin of Primary Tumour {Cancer} coded as Brain/CNS Cancer; AND Most Valid Basis of Diagnosis {Cancer} coded as Histology of metastasis, or Histology of primary [ICDSITE = C700 OR C701 OR C709 OR C71 OR C72 OR C75.2 OR C75.3] AND [VALID = 6 OR 7] numerator exclusion Include in the denominator measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [PATHCOMPL = 99] Include in the denominator measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion this standard. N/A denominator Exclude from the denominator measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion this standard [ICDSITE = C99.X] OR [VALID = 99] Brain/CNS Cancer QPI Measurability v3.0 10
11 QPI 5 Pre-Treatment Magnetic Resonance Imaging (MRI) QPI Title: Numerator: Patients with brain/central nervous system (CNS) cancer should have contrast enhanced Magnetic Resonance Imaging (MRI) prior to treatment. Proportion of patients with brain/cns cancer undergoing surgery, who have a contrast enhanced MRI prior to treatment. Number of patients with brain/cns cancer undergoing surgery who receive a contrast enhanced MRI prior to treatment. MRI SCAN (Pre-treatment) coded as Yes; AND Date MRI Scan (Pre-treatment) is bee or equal to Date of First Surgical Procedure [MRI = 1] AND [MRIDATE DFIRSTSURG] Denominator: All patients with brain/cns cancer undergoing surgery (Excluding Patients unable to undergo a contrast enhanced MRI scan (e.g.pacemaker or other MRI incompatible implanted device; Claustrophobia; Patients who refuse MRI; and Patients with Contraindication to intravenous contrast medium;. Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Site of Origin of Primary Tumour {Cancer} coded as Brain/CNS Cancer; AND Date of First Surgical Procedure not coded as inapplicable AND MRI (Pre-treatment) not coded as Patient refused investigation, Contraindication to intravenous contrast medium, or Clinically inappropriate [ICDSITE = C700 OR C701 OR C709 OR C71 OR C72 OR C75.2 OR C75.3] AND [DFIRSTSURG <> 10/10/1010] AND [MRI<> (95 OR 97 OR 98)] numerator exclusion Include in the denominator measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [MRI = 99] OR [MRIDATE] Include in the denominator measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion this standard. [MRI = 99] denominator Exclude from the denominator measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion this standard [ICDSITE = C99.X] OR [DFIRSTSURG = 09/09/0909] Brain/CNS Cancer QPI Measurability v3.0 11
12 QPI 6 Maximal Surgical Resection QPI Title: Wherever possible patients should undergo maximal surgical resection of malignant gliomas d. Numerator : Proportion of patients with malignant glioma d (with enhancing component on pre-operative imaging) who undergo surgical resection where 90% reduction in tumour volume is achieved provided it is considered consistent with safe outcome. Number of patients with resectable malignant glioma d (with enhancing component on pre-operative imaging) undergoing surgical resection where 90%* reduction in tumour volume is achieved. Reduction in Tumour Volume {Brain/CNS Cancer} coded as % [REDUCT = 5] Denominator All patients with malignant glioma d (with enhancing component on pre-operative imaging) undergoing surgical resection. (Excluding patients undergoing biopsy only d, and Patients in whom surgeons intent is partial resection / debulking surgery). Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Morphology of Tumour coded as Anaplastic astrocytoma; Glioblastoma; Giant cell glioblastoma; Gliosarcoma; Oligodendroglioma; Anaplastic Oligodendroglioma; Oligoastrocytoma; Anaplastic Oligoastrocytoma; Anaplastic pleomorphic xanthoastrocytoma; Anaplastic ependymoma; AND Main Type of Definitive Surgery {Brain/CNS Cancer} coded as Craniotomy lesion of frontal lobe, Craniotomy lesion of temporal lobe, Craniotomy lesion of parietal lobe, Craniotomy lesion of occipital lobe, Craniotomy lesion of cerebellum, Craniotomy lesion of brain tissue - other site AND Enhancing component present on pre-operative imaging coded as yes; AND Intent of Surgery not coded as partial resection / debulking surgery [MORPHOL = 9401/3 OR 9440/3 OR 9441/3 OR 9442/3 OR 9445/3 OR 9450/3 OR 9451/3 OR 9424/3 OR 9392/3] AND [OPCODE1 OR OPCODE2 OR OPCODE3 OR OPCODE4 = A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8] AND [ENHANC = 1] AND [OPINTENT <> 2] numerator Include in the denominator measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [REDUCT = 99] Include in the denominator measurement against the target unless there is other definitive evidence that the record should be excluded. d Malignant gliomas include: Glioblastoma multime- GBM and its variants e.g. gliosarcoma) Anaplastic Astrocytoma- AA) Anaplastic pleomorphic xanthoastrocytoma Aanaplastic oligodendrogliomas Anaplastic (High-grade) ependymoma e Patients undergoing biopsy only are excluded by default due to the operation codes used within this measurability Brain/CNS Cancer QPI Measurability v3.0 12
13 exclusion Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion this standard. denominator [OPINTENT = 99] Exclude from the denominator measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion this standard (i) [MORPHOL = 9999/9] OR [OPCODE1 = 99 AND OPCODE2-4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8) OR OPCODE2 = 99 AND OPCODE1, 3, 4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8) OR OPCODE3 = 99 AND OPCODE 1, 2, 4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8) OR OPCODE4 = 99 AND OPCODE1-3 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8)] OR [ENHANC = 99] *Percentage tumour reduction should be assessed by comparing pre surgical imaging to post surgical 72hr Magnetic Resonance Imaging (MRI) Brain/CNS Cancer QPI Measurability v3.0 13
14 QPI 7 Early Post-Operative Imaging QPI Title: Numerator: Patients with malignant glioma d (with enhancing component on pre-operative imaging) undergoing surgical resection should be subject to early post-operative imaging. Proportion of patients with malignant glioma d, (with enhancing component on pre-operative imaging) who receive early post operative imaging with Magnetic Resonance Imaging (MRI) within 3 days (72hrs) of surgical resection. Number of patients with malignant glioma d, (with enhancing component on pre-operative imaging) undergoing surgical resection who receive MRI within 3 days (72hrs) of surgical resection. Date of Post Surgical MRI SCAN minus Date of Definitive Surgery less than or equal to 3 [POSTMRIDATE DSURG 3] Denominator: NB Dates do not allow specification in hours All patients with malignant glioma d, (with enhancing component on pre-operative imaging), undergoing surgical resection. (Excluding Patients unable to undergo an MRI scan (e.g.pacemaker or other MRI incompatible implanted device; Cerebral aneurysm clip; Patients who refuse MRI; Contraindication to intravenous contrast medium; and Patients undergoing biopsy only e ). Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Morphology of Tumour coded as Anaplastic astrocytoma; Glioblastoma; Giant cell glioblastoma, Gliosarcoma; Oligodendroglioma; Anaplastic Oligodendroglioma; Oligoastrocytoma; Anaplastic Oligoastrocytoma; Anaplastic pleomorphic xanthoastrocytoma; Anaplastic ependymoma; AND Main Type of Definitive Surgery {Brain/CNS Cancer} coded as Craniotomy lesion of frontal lobe, Craniotomy lesion of temporal lobe, Craniotomy lesion of parietal lobe, Craniotomy lesion of occipital lobe, Craniotomy lesion of cerebellum, Craniotomy lesion of brain tissue - other site ; AND Enhancing component present on pre-operative imaging coded as yes; AND Post Surgical MRI SCAN not coded as Patient refused investigation,, Contraindication to intravenous contrast medium, or Clinically inappropriate. [MORPHOL = 9401/3 OR 9440/3 OR 9441/3 OR 9442/3 OR 9445/3 OR 9450/3 OR 9451/3 OR 9424/3 OR 9392/3] AND [OPCODE1 OR OPCODE2 OR OPCODE3 OR OPCODE4 = A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 ] AND [ENHANC = 1] AND [POSTMRI <> (95 OR 97 OR 98)] Include in the denominator measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as d Malignant gliomas include: Glioblastoma multime- GBM and its variants e.g. gliosarcoma) Anaplastic Astrocytoma- AA) Anaplastic pleomorphic xanthoastrocytoma Aanaplastic oligodendrogliomas Anaplastic (High-grade) ependymoma e Patients undergoing biopsy only are excluded by default due to the operation codes used within this measurability Brain/CNS Cancer QPI Measurability v3.0 14
15 numerator having met/not met the target [POSTMRIDATE = 09/09/0909] OR [DSURG = 09/09/0909] exclusion Include in the denominator measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion this standard. [POSTMRI = 99] denominator Exclude from the denominator measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion this standard [MORPHOL = 9999/9] OR [OPCODE1 OR OPCODE2 OR OPCODE3 OR OPCODE4 = 99] OR [ENHANC = 99] Brain/CNS Cancer QPI Measurability v3.0 15
16 QPI 8 Specialist Neuro-Oncology Access QPI Title: Patients with brain/central nervous system (CNS) cancer undergoing oncological treatment should be managed by a site specialist neurooncologist. Numerator: Proportion of patients with brain/cns cancer undergoing oncological treatment (chemotherapy or radiotherapy) who are managed by a specialist neuro-oncologist. Number of patients with brain/cns cancer undergoing oncological treatment (chemotherapy or radiotherapy) who are managed by specialist neuro-oncologist. Specialist Neuro-oncologist {Brain/CNS Cancer} coded as Yes [SPECNEURO = 01] Denominator: All patients with brain/cns cancer undergoing oncological treatment (chemotherapy or radiotherapy) (No exclusions). Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Site of Origin of Primary Tumour {Cancer} coded as Brain/CNS Cancer; AND (Radiotherapy Course Type {Brain/CNS Cancer} 1-2 coded as Radical, Palliative, or Chemoradiotherapy; OR Type of Systemic Anti-Cancer Therapy (SACT) (Brain/CNS Cancer) 1-2 coded as Adjuvant, Neoadjuvant, Palliative, Chemoradiotherapy, or Biological Therapy) [ICDSITE = C700 OR C701 OR C709 OR C71 OR C72 OR C75.2 OR C75.3] AND ( [RADIO1 OR RADIO2 = 3 OR 4 OR 7] OR [CHEMTYPE1 OR CHEMTYPE2 = 1 OR 2 OR 4 OR 5 OR 7] ) numerator exclusion Include in the denominator measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [SPECNEURO = 99] Include in the denominator measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion this standard. N/A denominator Exclude from the denominator measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion this standard [ICDSITE = 99] OR [RADIO1 OR RADIO2 = 99] OR [CHEMTYPE1 OR CHEMTYPE2= 99] Brain/CNS Cancer QPI Measurability v3.0 16
17 QPI 9 Access to Oncological Treatment QPI Title: The maximum time between surgery and oncological treatment patients with high grade glioma (WHO grades III and IV) should be 6 weeks. Numerator: Denominator: numerator exclusion denominator Proportion of patients with high grade glioma (WHO grades III and IV) undergoing surgery who commence their oncological treatment (chemotherapy, radiotherapy or chemoradiotherapy) within 6 weeks of surgery. Number of patients with high grade glioma (WHO grades III and IV) who undergo oncological treatment (chemotherapy, radiotherapy or chemoradiotherapy) who commence treatment within 6 weeks of surgery. Date Treatment Started {Cancer} (Radiotherapy) 1; or Date Treatment Started Systemic Anti-Cancer Therapy (SACT) 1 minus Date of Definitive Surgery is less than or equal to 42 [RADDATE1 DSURG 42] OR [CHEMDATE1 DSURG 42] ) All patients with high grade glioma (WHO grades 3 and 4) who undergo oncological treatment (chemotherapy, radiotherapy or chemoradiotherapy) following surgery. (No exclusions) Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Morphology of Tumour coded as Anaplastic astrocytoma; Glioblastoma; Giant cell glioblastoma, Gliosarcoma; Oligodendroglioma; Anaplastic Oligodendroglioma; Oligoastrocytoma; Anaplastic Oligoastrocytoma; Anaplastic pleomorphic xanthoastrocytoma; Anaplastic ependymoma; AND WHO Grade coded as Grade III or Grade IV; AND Main Type of Definitive Surgery {Brain/CNS Cancer} 1-4 coded as Craniotomy lesion of; frontal lobe, temporal lobe, parietal lobe, occipital lobe, cerebellum or brain tissue other site, biopsy only AND Radiotherapy Course Type {Brain/CNS Cancer} 1 coded as radical or chemoradiotherapy; or Type of Systemic Anti-Cancer Therapy (SACT) {Brain/CNS Cancer} 1 coded as adjuvant or chemoradiotherapy. [MORPHOL = 9401/3 OR 9440/3 OR 9441/3 OR 9442/3 OR 9445/3 OR 9450/3 OR 9451/3 OR 9424/3 OR 9392/3] AND [GRADE = 3 OR 4] AND ([OPCODE1 OR OPCODE2 OR OPCODE3 OR OPCODE4 = A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98]) AND ([RADIO1 =3 or 7] OR [CHEMTYPE1 = 1 or 5]) Include in the denominator measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target ([RADDATE1 = 09/09/0909] AND [CHEMDATE1 = 09/09/0909]) OR [DSURG = 09/09/0909] Include in the denominator measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion this standard. N/A Exclude from the denominator measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion this standard [MORPHOL = 9999/9] OR [GRADE = 99] OR [OPCODE1 = 99 AND OPCODE2-4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98) OR OPCODE2 = 99 AND OPCODE1, 3, 4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98) OR Brain/CNS Cancer QPI Measurability v3.0 17
18 OPCODE3 = 99 AND OPCODE 1, 2, 4 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98) OR OPCODE4 = 99 AND OPCODE1-3 <> (A02.1 OR A02.2 OR A02.3 OR A02.4 OR A02.5 OR A02.8 OR 98)] OR [(RADIO1 = 99 AND CHEMTYPE1 <>(1 OR 5)] OR [(CHEMTYPE1 = 99 AND RADIO1 <> (3 OR 7)] Brain/CNS Cancer QPI Measurability v3.0 18
19 QPI 10 Radical Radiotherapy Planning Process QPI Title: Numerator: The radical f radiotherapy planning process patients with brain/central Nervous System (CNS) cancer should include Magnetic Resonance Imaging (MRI) fusion. Proportion of patients with brain/cns cancer undergoing radical radiotherapy whom the radiotherapy planning process includes MRI fusion. Number of patients with primary brain/cns cancer undergoing radical radiotherapy whom radiotherapy planning includes MRI fusion. MRI Fusion in Radiotherapy Planning {Brain/CNS Cancer} coded as Yes MRI fusion included [MRIFUS = 1] Denominator: All patients with brain/cns cancer undergoing radical radiotherapy (Excluding Patients unable to undergo an MRI scan e.g. Pacemaker or other MRI incompatible implanted device; Cerebral aneurysm clip; Patients who refuse MRI, Contraindication to intravenous contrast medium) Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Site of Origin of Primary Tumour {Cancer} coded as Brain/CNS Cancer;; AND (Radiotherapy Course Type {Brain/CNS Cancer} 1-2 coded as Radical or Chemoradiotherapy; AND MRI Fusion in Radiotherapy Planning {Brain/CNS Cancer} not coded as Clinically inappropriate or Not applicable or Patient Refused or Contraindication to Intravenous Contrast Medium [ICDSITE = C700 OR C701 OR C709 OR C71 OR C72 OR C75.2 OR C75.3] AND [RADIO1 OR RADIO2 = 3 or 7] AND [MRIFUS <> 95 OR 96 OR 97 OR 98] numerator exclusion Include in the denominator measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [MRIFUS = 99] Include in the denominator measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion this standard. [MRIFUS = 99] denominator Exclude from the denominator measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion this standard [ICDSITE = 99] OR [RADIO1 OR RADIO2 = 99] f Radical is defined as radiotherapy courses where 15 fractions are delivered. Brain/CNS Cancer QPI Measurability v3.0 19
20 QPI 11 Seizure Management QPI Title: Numerator Patients with brain/central nervous system (CNS) cancer presenting with seizures at diagnosis should be seen by a neurologist and/or a named epilepsy specialist nurse (ESN). Proportion of patients with brain/cns cancer presenting with seizures at diagnosis who are seen by a neurologist or a named ESN within four weeks of diagnosis. Number of patients presenting with seizures at diagnosis seen by a neurologist or a named ESN within four weeks of diagnosis. Seen by Neurologist and/or Nurse with Expertise in Epilepsy Management {Brain/CNS Cancer} coded as seen by Named Epilepsy Specialist Nurse (ESN) or Neurologist or Seen by both (Named Epilepsy Specialist Nurse and Neurologist); AND Date seen by Neurologist and/or Named Epilepsy Specialist Nurse minus Date of Diagnosis less than or equal to 28 days.. [EPILNESN = 1 OR 2 OR 3] AND [EPILNESNDATE DIAGDATE 28] Denominator All brain/cns cancer patients presenting with seizures at diagnosis (No exclusions) Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Site of Origin of Primary Tumour {Cancer} coded as Brain/CNS Cancer; AND Seizure Presentation coded as Yes [ICDSITE = C700 OR C701 OR C709 OR C71 OR C72 OR C75.2 OR C75.3] AND [EPIL = 01] numerator exclusion Include in the denominator measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [EPILNESN = 99] OR [EPILNESNDATE = 09/09/0909] Include in the denominator measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion this standard. N/A denominator Exclude from the denominator measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion this standard [ICDSITE = C99.X] OR [EPIL = 99] Brain/CNS Cancer QPI Measurability v3.0 20
21 QPI 12 Key Worker QPI Title: Patients with brain/central nervous system (CNS) cancer should have an identified key worker to co-ordinate care across the patient pathway. Numerator Proportion of patients with brain/cns cancer who have an identified key worker by the first MDT meeting. Number of patients with brain/cns cancer who have an identified key worker by the first MDT meeting. Key Worker {Brain/CNS} coded as Yes [KEYWORK = 1] Denominator All patients with Brain/CNS cancer (Excluding patients undergoing supportive care). Date of Diagnosis [DIAGDATE] in range specified comparative analysis; AND Site of Origin of Primary Tumour {Brain/CNS Cancer} 1-4 coded as Brain/CNS Cancer; AND Type of First Cancer Treatment {Brain / CNS} not coded as supportive care. [ICDSITE = C700 OR C701 OR C709 OR C71 OR C72 OR C75.2 OR C75.3] AND [FIRSTTREATTYPE <> 7] numerator exclusion Include in the denominator measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [KEYWORK = 99] Include in the denominator measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion this standard. [FIRSTTREATTYPE = 99] denominator Exclude from the denominator measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion this standard [ICDSITE = C99.X] Brain/CNS Cancer QPI Measurability v3.0 21
22 QPI Day Mortality after Treatment Brain/CNS Cancer QPI Title: Numerator 30 day mortality following treatment brain/central nervous system (CNS) cancer. Proportion of patients with brain/cns cancer who die within 30 days of treatment (surgery, radiotherapy and chemotherapy) brain/cns cancer. Number of patients with brain/cns cancer who undergo treatment that die within 30 days of treatment. Date of Death is not coded as inapplicable and is within 30 days of date of active treatment [either DSURG / RCOMPDATE / CHEMENDATE] Surgery [DOD <> 10/10/1010] AND [DOD DSURG 30] Radiotherapy [DOD <> 10/10/1010] AND (([RADIO1 = 03 OR 04] AND [DOD RCOMPDATE1 30]) OR ([RADIO2 = 03 OR 04] AND [DOD RCOMPDATE2 30] )) Chemotherapy [DOD <> 10/10/1010] AND (([CHEMTYPE1 = 01 OR 02 OR 04] AND [DOD CHEMENDATE1 30]) OR ([CHEMTYPE2 = 01 OR 02 OR 04] AND [DOD CHEMENDATE2 30] )) Chemoradiotherapy ( ([CHEMTYPE1 = 5] AND [DOD - CHEMENDATE1 30] AND [CHEMENDATE1 <> 10/10/1010] ) OR ([CHEMTYPE2 = 5] AND [DOD CHEMENDATE2 30] AND [CHEMENDATE2 <> 10/10/1010] ) OR ([RADIO1 = 7] AND [DOD RCOMPDATE1 30] AND [RCOMPDATE1 <> 10/10/1010] ) OR ([RADIO2 = 7] AND [DOD RCOMPDATE2 30] AND [RCOMPDATE2 <> 10/10/1010] ) ) AND [DOD <> 10/10/1010] Brain/CNS Cancer QPI Measurability v3.0 22
Data Definitions for the National Minimum Core Dataset to support the introduction of Brain/CNS Quality Performance Indicators
Brain/CNS Cancer Data Definitions for the National Minimum Core Dataset to support the introduction of Brain/CNS Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration with
More informationBrain and Central Nervous System Cancer Clinical Quality Performance Indicators
Scottish Cancer Taskforce National Cancer Quality Steering Group Brain and Central Nervous System Cancer Clinical Quality Performance Indicators Published: December 2013 Updated: January 2016 (v2.1) March
More informationAudit Report. Brain and CNS Cancer Quality Performance Indicators. Report of the 2014 Clinical Audit Data
North, South East and West of Scotland Cancer Networks Neuro-Oncology Cancers Audit Report Brain and CNS Cancer Quality Performance Indicators Report of the 2014 Clinical Audit Data Dr Avinash Kanodia
More informationExamining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.
Stratified Medicine Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Looking in detail at cancer cells and their genetic make up. Permit
More informationData Definitions for the National Minimum Core Dataset to Support the Introduction of Bladder Cancer Quality Performance Indicators
Bladder Cancer Data Definitions for the National Minimum Core Dataset to Support the Introduction of Bladder Cancer Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration
More informationData Definitions for the National Minimum Core Dataset to Support the Introduction of Bladder Cancer Quality Performance Indicators
Bladder Cancer Data Definitions for the National Minimum Core Dataset to Support the Introduction of Bladder Cancer Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration
More informationData Definitions for the National Minimum Core Data Set to support the introduction of Cervical Cancer Quality Performance Indicators
Cervical Cancer Data Definitions for the National Minimum Core Data Set to support the introduction of Cervical Cancer Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration
More informationData Definitions for the National Minimum Core Data Set to support the introduction of Testicular Cancer Quality Performance Indicators
Testicular Cancer Data Definitions for the National Minimum Core Data Set to support the introduction of Testicular Cancer Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration
More informationData Definitions for the National Minimum Core Dataset to Support the Introduction of Bladder Cancer Quality Performance Indicators
Bladder Cancer Data Definitions for the National Minimum Core Dataset to Support the Introduction of Bladder Cancer Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration
More informationActivity Report April 2012 to March 2013
North, South East and West of Scotland Cancer Networks Brain/Central Nervous System Tumours National Managed Clinical Network Activity Report April 2012 to March 2013 Professor Roy Rampling Emeritus Professor
More informationData Definitions for the National Minimum Core Data Set to support the introduction of Testicular Cancer Quality Performance Indicators
Testicular Cancer Data Definitions for the National Minimum Core Data Set to support the introduction of Testicular Cancer Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration
More informationBrain and Central Nervous System Cancer Clinical Quality Performance Indicators
Scottish Cancer Taskforce Brain and Central Nervous System Cancer Clinical Quality Performance Indicators Published: December 2013 Updated: January 2016 (v2.1) Published by: Healthcare Improvement Scotland
More informationData Definitions for the National Minimum Core Data Set to support the introduction of Testicular Cancer Quality Performance Indicators
Testicular Cancer Data Definitions for the National Minimum Core Data Set to support the introduction of Testicular Cancer Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration
More informationImaging for suspected glioma
Imaging for suspected glioma 1.1.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless
More informationData Definitions for the National Minimum Core Data Set to support the introduction of Endometrial Cancer Quality Performance Indicators
Endometrial Cancer Data Definitions for the National Minimum Core Data Set to support the introduction of Endometrial Cancer Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration
More informationOvarian Cancer Quality Performance Indicators
Ovarian Cancer Quality Performance Indicators Patients diagnosed between October 2013 and September 2016 Publication date 20 February 2018 An Official Statistics publication for Scotland This is an Official
More informationOESOPHAGO-GASTRIC CANCER 2016
SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT OESOPHAGO-GASTRIC CANCER 2016 COMPARATIVE AUDIT REPORT Mr Peter Lamb SCAN Lead Upper GI Cancer Clinician Dr Jonathan Fletcher, Consultant Physician,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationData Definitions for the National Minimum Core Dataset to Support the Introduction of Upper GI Quality Performance Indicators
Upper GI Cancer Data Definitions for the National Minimum Core Dataset to Support the Introduction of Upper GI Quality Performance Indicators Definitions developed by ISD Scotland in collaboration with
More informationCorporate Medical Policy
Corporate Medical Policy Analysis of MGMT Promoter Methylation in Malignant Gliomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: analysis_of_mgmt_promoter_methylation_in_malignant_gliomas
More informationMOLECULAR DIAGNOSTICS OF GLIOMAS
MOLECULAR DIAGNOSTICS OF GLIOMAS Arie Perry, M.D. Director, Neuropathology Division DIFFUSE GLIOMAS Cell types Astrocytomas (A) Oligodendrogliomas (O) Mixed oligoastrocytoma (MOA) Three WHO grades: II,
More informationData Definitions for the National Minimum Core Dataset to support the Introduction of Colorectal Quality Performance Indicators
Colorectal Cancer Data Definitions for the National Minimum Core Dataset to support the Introduction of Colorectal Quality Performance Indicators Definitions developed by ISD Scotland in collaboration
More informationTechnology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 NICE 2018. All rights reserved.
More informationSite Specific Coding Rules MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS
Multiple Primary and Histology Site Specific Coding Rules MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways
More informationData Definitions for the National Minimum Core Dataset to Support the Introduction of Upper GI Quality Performance Indicators
Upper GI Cancer Data Definitions for the National Minimum Core Dataset to Support the Introduction of Upper GI Quality Performance Indicators Definitions developed by ISD Scotland in collaboration with
More informationNational Breast Cancer Audit next steps. Martin Lee
National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationColorectal Cancer Comparative Audit Report
SOUTH EAST SCOTLAND CANCER NETWORK (SCAN) PROSPECTIVE CANCER AUDIT Colorectal Cancer 2014 2015 Comparative Audit Report Mr B.J. Mander, NHS Lothian, Lead Colorectal Cancer Clinician, SCAN Group Chair Mr
More informationAudit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed January December Published: November 2017
Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed January December 2016 Published: November 2017 Hardy Remmen NOSCAN Lung Cancer MCN Clinical
More informationGliomas in the 2016 WHO Classification of CNS Tumors
Gliomas in the 2016 WHO Classification of CNS Tumors Hindi N Al-Hindi, MD, FCAP Consultant Neuropathologist and Head Section of Anatomic Pathology Department of Pathology and Laboratory Medicine King Faisal
More informationThe New WHO Classification and the Role of Integrated Molecular Profiling in the Diagnosis of Malignant Gliomas
The New WHO Classification and the Role of Integrated Molecular Profiling in the Diagnosis of Malignant Gliomas Stefan Prokop, MD Neuropathology Fellow Hospital of the University of Pennsylvania Background
More informationPrimary brain tumours and cerebral metastases workshop
Primary brain tumours and cerebral workshop 22.4.16 Summary of workshop group discussions on the content of the scope Scope section Title: Primary brain tumours and cerebral Who the guideline is for People
More informationAudit Report. Colorectal Cancer Quality Performance Indicators. Patients diagnosed April 2016 March Published: March 2018
Colorectal Cancer Managed Clinical Network Audit Report Colorectal Cancer Quality Performance Indicators Patients diagnosed April 2016 March 2017 Published: March 2018 Mr Michael Walker NOSCAN MCN Clinical
More informationData Definitions for the National Minimum Core Dataset to support the Introduction of Lymphoma Quality Performance Indicators
Lymphoma Data Definitions for the National Minimum Core Dataset to support the Introduction of Lymphoma Quality Performance Indicators Definitions developed by ISD Scotland in collaboration with the Lymphoma
More informationData Definitions for the National Minimum Core Dataset to Support the Introduction of Lung Cancer Quality Performance Indicators
Lung Cancer Data Definitions for the National Minimum Core Dataset to Support the Introduction of Lung Cancer Quality Performance Indicators Definitions developed by ISD Scotland in collaboration with
More informationAudit Report. Colorectal Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: July 2016
NORTH OF SCOTLAND PLANNING GROUP Colorectal Cancer Managed Clinical Network Audit Report Colorectal Cancer Quality Performance Indicators Patients diagnosed April 2014 March 2015 Published: July 2016 Mr
More informationActivity Report April 2014 March 2015
North, South East and West of Scotland Cancer Networks Brain/Central Nervous System Tumours National Managed Clinical Network Activity Report April 2014 March 2015 Dr Avinash Kanodia Consultant Radiologist
More informationMALIGNANT GLIOMAS: TREATMENT AND CHALLENGES
MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES DISCLOSURE No conflicts of interest to disclose Patricia Bruns APRN, CNS Givens Brain Tumor Center Abbott Northwestern Hospital October 12, 2018 OBJECTIVES THEN
More informationHead and Neck QPI Group Audit Report Head and Neck Quality Performance Indicators Consultant Clinical Oncologist, NHS Grampian
Head and Neck QPI Group Audit Report Head and Neck Quality Performance Indicators Patients diagnosed April 2016 March 2017 Published: February 2018 Dr Rafael Moleron Consultant Clinical Oncologist, NHS
More informationNICE guideline Published: 11 July 2018 nice.org.uk/guidance/ng99
Brain tumours (primary) and brain metastases in adults NICE guideline Published: 11 July 2018 nice.org.uk/guidance/ng99 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationData Definitions for the National Minimum Core Dataset to support the Introduction of Lymphoma Quality Performance Indicators
Lymphoma Data Definitions for the National Minimum Core Dataset to support the Introduction of Lymphoma Quality Performance Indicators Definitions developed by ISD Scotland in collaboration with the Lymphoma
More informationAudit Report. Cervical Cancer Quality Performance Indicators. Patients diagnosed October 2014 September Published: September 2016
Gynaecology Managed Clinical Network NORTH OF SCOTLAND PLANNING GROUP Audit Report Cervical Cancer Quality Performance Indicators Patients diagnosed October 2014 September 2015 Published: September 2016
More informationData Definitions for the National Minimum Core Dataset to Support the Introduction of Lung Cancer Quality Performance Indicators
Lung Cancer Data Definitions for the National Minimum Core Dataset to Support the Introduction of Lung Cancer Quality Performance Indicators Definitions developed by ISD Scotland in collaboration with
More informationUpper GI Cancer Quality Performance Indicators
Publication Report Upper GI Cancer Quality Performance Indicators Patients diagnosed during January 2013 to December 2015 Publication date 28 th March 2017 An Official Statistics Publication for Scotland
More informationHepatopancreaticobiliary (HPB) Cancer
Hepatopancreaticobiliary (HPB) Cancer Data Definitions for the National Minimum Core Dataset to support the Introduction of HPB Quality Performance Indicators Definitions developed by ISD Scotland in collaboration
More informationClinical Audit Data: 01 October 2015 to 30 September West of Scotland Cancer Network. Gynaecological Cancer Managed Clinical Network
Gynaecological Cancer Managed Clinical Network Audit Report Ovarian Cancer Quality Performance Indicators Cervical Cancer Quality Performance Indicators Endometrial Cancer Quality Performance Indicators
More informationData Definitions for the National Minimum Core Dataset to Support the Introduction of
Head and Neck Cancer Data Definitions for the National Minimum Core Dataset to Support the Introduction of Head and Neck Cancer Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration
More informationCOLORECTAL CANCER Quality Performance Indicators (QPI) Comparative Report
SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT COLORECTAL CANCER 2016 2017 Quality Performance Indicators (QPI) Comparative Report Mr S Yalamarthi, NHS Fife, Lead Colorectal Cancer Clinician,
More informationColorectal Cancer Quality Performance Indicators
Publication Report Colorectal Cancer Quality Performance Indicators Patients diagnosed between April 2013 and March 2016 Publication date 27th June 2017 An Official Statistics Publication for Scotland
More informationData Definitions for the National Minimum Core Dataset to Support the Introduction of Prostate Quality Performance Indicators
Prostate Cancer Data Definitions for the National Minimum Core Dataset to Support the Introduction of Prostate Quality Performance Indicators Definitions developed by ISD Scotland in collaboration with
More informationAudit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: May 2016
NORTH OF SCOTLAND PLANNING GROUP Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed April 2014 March 2015 Published: May 2016 Mr Hardy Remmen
More informationData Definitions for the National Minimum Core Dataset to support the Introduction of Colorectal Quality Performance Indicators
Colorectal Cancer Data Definitions for the National Minimum Core Dataset to support the Introduction of Colorectal Quality Performance Indicators Definitions developed by ISD Scotland in collaboration
More informationAudit Report Endometrial & Cervical Cancer Quality Performance Indicators
Gynaecological Cancer Managed Clinical Network Audit Report Endometrial & Cervical Cancer Quality Performance Indicators Clinical Audit Data: 01 October 2014 to 30 September 2015 Nadeem Siddiqui Consultant
More informationAudit Report. Bladder Cancer Quality Performance Indicators. Patients diagnosed April 2015 March Published: May 2017
Urological Cancer Managed Clinical Network NORTH OF SCOTLAND PLANNING GROUP Audit Report Bladder Cancer Quality Performance Indicators Patients diagnosed April 2015 March 2016 Published: May 2017 Mr Sarfraz
More informationSupporting patients with brain tumours
Supporting patients with brain tumours Alison Corbett Macmillan Clinical Nurse Specialist Neuro-Oncology Women's cancers Breast cancer introduction 1 Key contributions that CNSs make to cancer care Tumour
More informationPROPOSED/DRAFT Local Coverage Determination (LCD): MolDX: Chromosome 1p/19q deletion analysis (DL36483)
moldx: Chromosome 1p/19q deletion analysis (DL36483) Page 1 of 8 PROPOSED/DRAFT Local Coverage Determination (LCD): MolDX: Chromosome 1p/19q deletion analysis (DL36483) Close Section Navigation
More informationData Definitions for the National Minimum Core Dataset to Support the Introduction of Prostate Quality Performance Indicators
Prostate Cancer Data Definitions for the National Minimum Core Dataset to Support the Introduction of Prostate Quality Performance Indicators Definitions developed by ISD Scotland in collaboration with
More informationClinical Management Protocol Chemotherapy [Glioblastoma Multiforme (CNS)] Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: GLIOBLASTOMA MULTIFORME (CNS) Patient information given at each stage following agreed
More informationAudit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: February 2018
Breast Cancer Managed Clinical Network Audit Report Breast Cancer Quality Performance Indicators Patients diagnosed during 2016 Published: February 2018 Mr Douglas Brown NOSCAN Breast Cancer MCN Clinical
More informationNational Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)
National Institute for Health and Clinical Excellence Appendix C Comment 1: the draft scope Single Technology Appraisal (STA) Carmustine implants for the treatment of recurrent glioblastoma multiforme
More informationActivity Report April 2012 March 2013
Colorectal Cancer Managed Clinical Network Activity Report April 2012 March 2013 Paul Horgan Professor of Surgery MCN Clinical Lead Kevin Campbell Network Manager 1 CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION
More informationData Definitions for the National Minimum Core Dataset to support the Introduction of Colorectal Quality Performance Indicators
Colorectal Cancer Data Definitions for the National Minimum Core Dataset to support the Introduction of Colorectal Quality Performance Indicators Definitions developed by ISD Scotland in collaboration
More informationHepatopancreaticobiliary (HPB) Cancer
Hepatopancreaticobiliary (HPB) Cancer Data Definitions for the National Minimum Core Dataset to support the Introduction of HPB Quality Performance Indicators Definitions developed by ISD Scotland in collaboration
More informationHepatopancreaticobiliary (HPB) Cancer
Hepatopancreaticobiliary (HPB) Cancer Data Definitions for the National Minimum Core Dataset to support the Introduction of HPB Quality Performance Indicators Definitions developed by ISD Scotland in collaboration
More informationImproving services for upper GI (OG) cancer Application template (Version 2)
Trust Clinical lead Improving services for upper GI (OG) cancer Application template (Version 2) Managerial lead Date completed 14 June 2013 Barnet & Chase Farm Hospitals NHS Trust Dr Marta Carpani Upper
More informationQ&A. Fabulous Prizes. Collecting Cancer Data:CNS 2/7/12. NAACCR Webinar Series Collecting Cancer Data Central Nervous System
Collecting Cancer Data Central Nervous System NAACCR 2012 2013 Webinar Series 2/7/2013 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants
More informationData Definitions for the National Minimum Core Data Set to support the introduction of Sarcoma Quality Performance Indicators
Sarcoma Data Definitions for the National Minimum Core Data Set to support the introduction of Sarcoma Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration with the Sarcoma
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More informationEpithelial Ovarian Cancer
Epithelial Ovarian Cancer Data Definitions for the National Minimum Core Dataset to Support the Introduction of Epithelial Ovarian Quality Performance Indicators Definitions developed by ISD Scotland in
More informationGlioblastoma. In this fact sheet: What is a glioblastoma?
Glioblastoma Glioblastomas are the most common primary brain tumours in adults. (Primary means the tumour starts in the brain, rather than starting elsewhere in the body then spreading to the brain). It
More informationBrain tumours (primary) and brain metastases in adults
Brain tumours (primary) and brain metastases in adults NICE guideline Draft for consultation, January 0 This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain
More informationData Definitions for the National Minimum Core Dataset to Support the Introduction of Breast Quality Performance Indicators
Breast Cancer Data Definitions for the National Minimum Core Dataset to Support the Introduction of Breast Quality Performance Indicators Definitions developed by ISD Scotland in collaboration with the
More informationHistopathological Study and Categorisation of Brain Tumors
Histopathological Study and Categorisation of Brain Tumors Ruchira Wadhwa 1*, Purvi Patel 2, Hansa Goswami 3 1 Third Year Resident, 2 Assistant Professor, 3 Professor and Head, Department of Pathology,
More informationAudit Report. Upper GI Cancer Quality Performance Indicators. Report of the 2016 Clinical Audit Data. West of Scotland Cancer Network
Upper Gastro-intestinal Cancer Managed Clinical Network Audit Report Upper GI Cancer Quality Performance Indicators Report of the 216 Clinical Audit Data Mr Matthew Forshaw MCN Clinical Lead Tracey Cole
More informationData Definitions for the National Minimum Core Dataset to Support the Introduction of Breast Quality Performance Indicators
Breast Cancer Data Definitions for the National Minimum Core Dataset to Support the Introduction of Breast Quality Performance Indicators Definitions developed by ISD Scotland in collaboration with the
More informationAudit Report. Bladder Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network
Urological Cancer Managed Clinical Network Audit Report Bladder Cancer Quality Performance Indicators Clinical Audit Data: 01 April 2015 to 31 March 2016 Mr Gren Oades MCN Clinical Lead Tom Kane MCN Manager
More informationScottish Medicines Consortium
Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly
More informationCHINESE MEDICAL ASSOCIATION
Zhu et al. Chinese Neurosurgical Journal (2017) 3:22 DOI 10.1186/s41016-017-0087-2 CHINESE NEUROSURGICAL SOCIETY CASE REPORT CHINESE MEDICAL ASSOCIATION Anaplastic pleomorphic xanthoastrocytoma with disseminated
More informationProtocol for emergency surgical intervention in patients with a brain tumour v3
Protocol for emergency surgical intervention in patients with a brain tumour v3 West Midlands Cancer Alliance Coversheet for Cancer Alliance Expert Advisory Group Agreed Documentation This sheet is to
More informationNational Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator
National Cancer Peer Review Sarcoma Julia Hill Acting Deputy National Co-ordinator Improving Outcomes Guidance The Intentions of Improving Outcomes for People with Sarcoma Changes in the provision of care
More informationAudit Report Acute Leukaemia Quality Performance Indicators
Haemato-oncology Managed Clinical Network Audit Report Acute Leukaemia Quality Performance Indicators Clinical Audit Data: 01 July 2014 to 30 June 2017 Dr Mark Drummond Consultant Haematologist MCN Clinical
More informationChildhood Brain and Spinal Cord Tumors Treatment Overview (PDQ )
1 di 14 27/11/2016 17.42 NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute
More informationWhat do we know about GBM Patient pathways in England?
What do we know about GBM Patient pathways in England? Matt Williams, ICHNT David Greenberg, PHE On behalf of the NCIN Brain CNS SSCRG April 216 Background Previously published data on GBM incidence and
More informationClinical Commissioning Policy: Deep Brain Stimulation for Refractory Epilepsy
Clinical Commissioning Policy: Deep Brain Stimulation for Refractory Epilepsy Reference: NHS England xxx/x/x 1 Clinical Commissioning Policy: Deep Brain Stimulation for Refractory Epilepsy First published:
More informationData Definitions for the National Minimum Core Dataset to support the introduction of Melanoma Quality Performance Indicators
Melanoma Data Definitions for the National Minimum Core Dataset to support the introduction of Melanoma Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration with the Melanoma
More informationLOW GRADE ASTROCYTOMAS
LOW GRADE ASTROCYTOMAS This article was provided to us by David Schiff, MD, Associate Professor of Neurology, Neurosurgery, and Medicine at University of Virginia, Charlottesville. We appreciate his generous
More informationAudit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: December 2015 NORTH OF SCOTLAND PLANNING GROUP
NORTH OF SCOTLAND PLANNING GROUP Breast Cancer Managed Clinical Network Audit Report Breast Cancer Quality Performance Indicators Patients diagnosed during Published: December 2015 Mr Douglas Brown NOSCAN
More informationMolDX: Chromosome 1p/19q deletion analysis
MolDX: Chromosome 1p/19q deletion analysis CGS Administrators, LLC Jump to Section... Please Note: This is a Proposed LCD. Proposed LCDs are works in progress and not necessarily a reflection of the current
More informationRadioterapia no Tratamento dos Gliomas de Baixo Grau
Radioterapia no Tratamento dos Gliomas de Baixo Grau Dr. Luis Souhami University Montreal - Canada Low Grade Gliomas Relatively rare Heterogeneous, slow growing tumors WHO Classification Grade I Pilocytic
More informationAudit Report Report of the 2011 Clinical Audit Data
Lung Cancer Managed Clinical Network Audit Report Report of the 2011 Clinical Audit Data Dr Richard Jones Consultant Clinical Oncologist MCN Clinical Lead Kevin Campbell MCN Manager Julie McMahon Information
More informationAccuracy of intra-operative rapid diagnosis by Squash smear in CNS lesions An early institutional experience. KK Bansal,
Accuracy of intra-operative rapid diagnosis by Squash smear in CNS lesions An early institutional experience. KK Bansal, Monika Bansal, Sanjeev Kishore, Anuradha K, Meena H, Dushyant G. Department of Neurosurgery
More informationCNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.
CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage
More informationTesticular Cancer Quality Performance Indicators
Testicular Cancer Quality Performance Indicators Patients diagnosed between October 2014 and September 2017 Publication date 28 August 2018 An Official Statistics publication for Scotland This is an Official
More informationActivity Report April 2013 March 2014
North, South East and West of Scotland Cancer Networks HepatoPancreatoBiliary Cancers National Managed Clinical Network Activity Report April 2013 March 2014 Mr Colin McKay Consultant Surgeon NMCN Clinical
More informationAudit Report. Report of the 2010 Clinical Audit Data. West of Scotland Cancer Network. Lung Cancer Managed Clinical Network
West of Scotland Cancer Network Lung Cancer Managed Clinical Network Audit Report Report of the 2010 Clinical Audit Data Dr Richard Jones Consultant Clinical Oncologist MCN Clinical Lead Tracey Cole MCN
More informationEORTC (RTOG 0834 Endorsed) Opened: July 22, 2009
January 2011 0834-1 EORTC 26053 22054 (RTOG 0834 Endorsed) Protocol Status: Opened: July 22, 2009 Title: Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic
More informationCorporate Medical Policy
Corporate Medical Policy Brachytherapy, Intracavitary Balloon Catheter for Brain Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: brachytherapy_intracavitary_balloon_catheter_for_brain_cancer
More informationLung Cancer Quality Performance Indicators
Publication Report Lung Cancer Quality Performance Indicators Patients diagnosed during April 2013 to December 2015 Publication date 28 th February 2017 RESTRICTED STATISTICS Release embargoed until Tuesday
More informationData Definitions for the National Minimum Core Data Set to support the introduction of Sarcoma Quality Performance Indicators
Sarcoma Data Definitions for the National Minimum Core Data Set to support the introduction of Sarcoma Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration with the Sarcoma
More information